Abstract #0055

13C-Labeled Malate as a Treatment Response Marker in a Murine Lymphoma Model in Vivo

Rene in 't Zandt¹, Mikko Kettunen², Magnus Karlsson¹, Pernille Rose Jensen¹, Anna Gisselsson¹, Ferdia Gallagher^2,3, De Hu², Georg Hansson¹, Kevin Brindle², Mathilde Lerche¹

¹Imagnia AB, Malm, Sweden; ²Cancer Research UK Cambridge Research Institute and Dept. of Biochemistry, University of Cambridge, Cambridge, UK; ³Dept. of Radiology, Addenbrookes Hospital, University of Cambridge, Cambridge, UK

Early measurements of tumor responses to therapy have been shown to help predict the subsequent treatment outcome in many tumor cell lines. Previously it has been shown that the flux of hyperpolarized ¹³C label between pyruvate and lactate in a murine lymphoma model can be used as an early marker of cell death following chemotherapy both in vitro and in vivo. This study show that a promising new tumor biomarker - hyperpolarized [1,4-¹³C₂]fumarate - can be used in the same model to image the effects of chemotherapy.